111 related articles for article (PubMed ID: 23121822)
1. Mood and physical symptoms improve in women with severe cyclical changes by taking an oral contraceptive containing 250-mcg norgestimate and 35-mcg ethinyl estradiol.
Nyberg S
Contraception; 2013 Jun; 87(6):773-81. PubMed ID: 23121822
[TBL] [Abstract][Full Text] [Related]
2. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen.
Coffee AL; Kuehl TJ; Willis S; Sulak PJ
Am J Obstet Gynecol; 2006 Nov; 195(5):1311-9. PubMed ID: 16796986
[TBL] [Abstract][Full Text] [Related]
3. An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome.
Freeman EW; Halbreich U; Grubb GS; Rapkin AJ; Skouby SO; Smith L; Mirkin S; Constantine GD
Contraception; 2012 May; 85(5):437-45. PubMed ID: 22152588
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience with a new norgestimate-containing oral contraceptive.
Huber J
Int J Fertil; 1991; 36 Suppl 1():25-31. PubMed ID: 1678378
[TBL] [Abstract][Full Text] [Related]
5. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol.
Greco T; Graham CA; Bancroft J; Tanner A; Doll HA
Contraception; 2007 Jul; 76(1):8-17. PubMed ID: 17586130
[TBL] [Abstract][Full Text] [Related]
6. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
7. Comparison of scales for evaluating premenstrual symptoms in women using oral contraceptives.
Coffee AL; Kuehl TJ; Sulak PJ
Pharmacotherapy; 2008 May; 28(5):576-83. PubMed ID: 18447656
[TBL] [Abstract][Full Text] [Related]
8. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of psychiatric disorders and premenstrual dysphoric symptoms in patients with experience of adverse mood during treatment with combined oral contraceptives.
Segebladh B; Borgström A; Odlind V; Bixo M; Sundström-Poromaa I
Contraception; 2009 Jan; 79(1):50-5. PubMed ID: 19041441
[TBL] [Abstract][Full Text] [Related]
10. Effects of a triphasic combination oral contraceptive containing norgestimate/ethinyl estradiol on biochemical markers of bone metabolism in young women with osteopenia secondary to hypothalamic amenorrhea.
Grinspoon SK; Friedman AJ; Miller KK; Lippman J; Olson WH; Warren MP
J Clin Endocrinol Metab; 2003 Aug; 88(8):3651-6. PubMed ID: 12915650
[TBL] [Abstract][Full Text] [Related]
11. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
[TBL] [Abstract][Full Text] [Related]
12. Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24/4 regimen.
Marr J; Niknian M; Shulman LP; Lynen R
Contraception; 2011 Jul; 84(1):81-6. PubMed ID: 21664515
[TBL] [Abstract][Full Text] [Related]
13. Influence of alitretinoin on the pharmacokinetics of the oral contraceptive ethinyl estradiol/norgestimate.
Schmitt-Hoffmann AH; Roos B; Sauer J; Schleimer M; Schoetzau A; Leese PT; Weidekamm E; Maares J
Clin Exp Dermatol; 2011 Apr; 36 Suppl 2():4-11. PubMed ID: 21443598
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and tolerability of norgestimate/ethinyl estradiol (250 micrograms of norgestimate/35 micrograms of ethinyl estradiol): results of an open, multicenter study of 59,701 women.
Runnebaum B; Grunwald K; Rabe T
Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 2):1963-8. PubMed ID: 1605286
[TBL] [Abstract][Full Text] [Related]
15. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with a new norgestimate-containing oral contraceptive.
Huber J
Int J Fertil; 1992; 37 Suppl 1():47-53. PubMed ID: 1347520
[TBL] [Abstract][Full Text] [Related]
17. [Acceptance and subjective well-being with a norgestimate combination pill].
Schoberberger R; Husslein P; Kunze M
Gynakol Rundsch; 1991; 31(2):65-76. PubMed ID: 1916521
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder.
Freeman EW; Kroll R; Rapkin A; Pearlstein T; Brown C; Parsey K; Zhang P; Patel H; Foegh M;
J Womens Health Gend Based Med; 2001; 10(6):561-9. PubMed ID: 11559453
[TBL] [Abstract][Full Text] [Related]
19. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment.
Thorneycroft lH; Gollnick H; Schellschmidt I
Cutis; 2004 Aug; 74(2):123-30. PubMed ID: 15379365
[TBL] [Abstract][Full Text] [Related]
20. Long-term profile of a new progestin.
Lippman J
Int J Fertil; 1992; 37 Suppl 4():218-22. PubMed ID: 1362189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
